Drug updated on 12/11/2024
| Dosage Form | Injection (subcutaneous, 45 mg, 60 mg) |
| Drug Class | Activin signaling inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events.
Latest News
Summary
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- Sotatercept significantly improves pulmonary vascular resistance and World Health Organization (WHO) functional class in pulmonary arterial hypertension (PAH) patients compared to placebo, according to the second study's meta-analysis.
- Metformin shows potential PAH-modifying effects similar to sotatercept, though no direct comparative data is provided. Other drugs, including fasudil and anastrozole, require long-term studies to assess effectiveness, with no direct comparisons available in the evidence.
- The meta-analysis indicates that adverse events occurred at similar rates between sotatercept and placebo groups.
- A significant increase in hemoglobin levels was observed in the sotatercept group, which is noteworthy given that approximately 33% of PAH patients experience anemia, potentially affecting prognosis. No further details on specific adverse events or their frequencies are provided.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Winrevair (sotatercept-csrk) Prescribing Information. | 2024 | Merck & Co., Rahway, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| A Systematic Review of Novel Therapies of Pulmonary Arterial Hypertension | 2024 | American Journal of Cardiovascular Drugs |
| Navigating the Sotatercept landscape: A meta-analysis of clinical outcomes | 2024 | Clinical Cardiology |